Axsome Therapeutics (AXSM)
(Real Time Quote from BATS)
$93.89 USD
-1.95 (-2.04%)
Updated Sep 23, 2024 09:52 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 386 | 201 | 86 | 184 | 220 |
Receivables | 95 | 38 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 4 | 0 | 0 | 0 |
Other Current Assets | 8 | 3 | 0 | 0 | 0 |
Total Current Assets | 504 | 246 | 87 | 184 | 220 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 11 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 65 | 70 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 15 | 0 | 0 | 0 |
Total Assets | 588 | 331 | 88 | 186 | 221 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 3 |
Accounts Payable | 41 | 39 | 13 | 14 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 91 | 52 | 9 | 9 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 6 | 0 | 0 | 0 |
Total Current Liabilities | 139 | 97 | 23 | 23 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 178 | 94 | 49 | 48 | 17 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 73 | 31 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 397 | 222 | 72 | 72 | 42 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,027 | 706 | 425 | 393 | 355 |
Retained Earnings | -836 | -596 | -409 | -279 | -176 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 191 | 110 | 16 | 114 | 179 |
Total Liabilities & Shareholder's Equity | 588 | 331 | 88 | 186 | 221 |
Total Common Equity | 191 | 110 | 16 | 114 | 179 |
Shares Outstanding | 47.30 | 43.40 | 37.60 | 37.30 | 34.50 |
Book Value Per Share | 4.04 | 2.52 | 0.42 | 3.05 | 5.18 |
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 316 | 331 | 386 | 417 | 437 |
Receivables | 120 | 101 | 95 | 78 | 67 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 16 | 15 | 10 | 9 |
Other Current Assets | 12 | 12 | 8 | 7 | 6 |
Total Current Assets | 463 | 460 | 504 | 512 | 520 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 16 | 0 | 11 | 14 | 15 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 62 | 64 | 65 | 67 | 69 |
Deposits & Other Assets | 0 | 14 | 0 | 0 | 0 |
Total Assets | 548 | 546 | 588 | 601 | 612 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 61 | 54 | 41 | 29 | 43 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 117 | 83 | 91 | 78 | 65 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 6 | 6 | 7 | 6 |
Total Current Liabilities | 187 | 144 | 139 | 115 | 115 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 179 | 179 | 178 | 177 | 177 |
Non-Current Capital Leases | 3 | 2 | 0 | 0 | 0 |
Other Non-Current Liabilities | 70 | 73 | 32 | 34 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 445 | 402 | 397 | 331 | 333 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,086 | 1,048 | 1,027 | 1,006 | 954 |
Retained Earnings | -983 | -904 | -836 | -737 | -675 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 103 | 144 | 191 | 270 | 279 |
Total Liabilities & Shareholder's Equity | 548 | 546 | 588 | 601 | 612 |
Total Common Equity | 103 | 144 | 191 | 270 | 279 |
Shares Outstanding | 47.50 | 47.50 | 47.30 | 47.10 | 43.50 |
Book Value Per Share | 2.17 | 3.03 | 4.04 | 5.72 | 6.41 |